Clinical Trial Results:
An intra-individual randomized controlled study to evaluate the efficacy and tolerance of the product RV4421A BS0042 in association with a moderately potent topical corticosteroid in adults with Atopic Dermatitis
Summary
|
|
EudraCT number |
2014-002194-10 |
Trial protocol |
DE |
Global end of trial date |
09 Jul 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Dec 2018
|
First version publication date |
12 Dec 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RV4421A2013147
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pierre Fabre Dermo Cosmétique
|
||
Sponsor organisation address |
45 place Abel Gance, Boulogne, France, 92654
|
||
Public contact |
not applicable, proDERM GmbH, AHougardy@proDERM.de
|
||
Scientific contact |
not applicable, proDERM GmbH, AHougardy@proDERM.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Feb 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Jul 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Jul 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective will be to evaluate the benefit of the association of the product RV4421A BS0042 with a moderately potent topical corticosteroid compared with the moderately potent topical corticosteroid alone, in improvement of Atopic Dermatitis in adults, measured by the reduction of L-SCORAD at Day 3 (D3).
|
||
Protection of trial subjects |
This study was performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments, and in accordance with the EN ISO 14155 (2011) and national regulations.
The protocol and related documents (including the informed consent form) were submitted for approval to an independent Ethics Committees before the study set up, according to national régulations.
The first application of the associated product and test product was performed at investigational centre under the study personnel control in order to explain the way of use to the patient and to evaluate the immediate local tolerance.
Additionally to the test product (on one arm or leg), all patients received on both arms or legs an activetreatment by an appropriate, representative, widely used and in the European Union (EU) approved TCS for 10 days.
|
||
Background therapy |
No other therapy was used during the trial. The patient was allowed to apply any topical medication on face and body, except on both study arms or legs. For instance, topical treatments prescribed by the investigator for the other AD lesions than those on study arms or legs were allowed throughout the duration of the study. During the 2nd period of the study (from D10 to D24), in case of worsening of lesions on one/both arm(s) or leg(s) leading to the need of a product application, the patient was authorized to apply any product on his/her suitable arm(s) or leg(s). | ||
Evidence for comparator |
According to several guidelines for treatment of Atopic Dermatitis, potent steroids should be avoided and moderately potent Topical Corticosteroids (TCS) are recommended on areas where the skin is already thin, such as flexures. Desonide 0.1 % cream (LOCAPRED) has been chosen as TCS because it is one of the most prescribed TCS in France and it is commercialized in most of Europe. | ||
Actual start date of recruitment |
01 Oct 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 54
|
||
Worldwide total number of subjects |
54
|
||
EEA total number of subjects |
54
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
54
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
This superiority clinical study was conducted as a European, multicentre, randomized, open-label, controlled, intra-individual(right/left arm/leg) trial on 54 adults with moderate to severe AD with symmetric lesions on arms or popliteal fossa. All patients were recruited in 4 centres in Germany | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
The patients with a phototype > IV were not included in the study because of difficulties in assessing the local tolerance of the products on darker skin. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
First Period
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
First Group | |||||||||||||||
Arm description |
Left arm/popliteal fossa: twice daily application of the product RV4421A BS0042 in association with once daily application of TCS on the AD lesions (10 days) Right arm/ popliteal fossa: once daily application of TCS alone on the AD lesions | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
RV4421A-BS0042
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The test product had to be applied twice daily (morning and evening) on lesions of only one study arm or popliteal fossa according to randomization, after the associated product, if applicable. One fingertip unit of test product had to be applied on only one arm or popliteal fossa, at each application. If the patient presented other lesions on the same arm or the same leg, he would also apply the test product on these lesions. The first application of test product was performed at the investigational centre.
|
|||||||||||||||
Investigational medicinal product name |
topical corticosteroid (TCS)
|
|||||||||||||||
Investigational medicinal product code |
Locapred 0.1%
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The TCS was applied once daily (evening only) on lesions of both study arms or popliteal fossa, before the test product if applicable. Two fingertip units of TCS were applied per study arm or popliteal fossa, at each application. If the patient presented other lesions on the study arm(s) or leg(s), he also applied the associated product on these lesions. The first application of TCS was performed at the investigational centre.
|
|||||||||||||||
Arm title
|
Second Group | |||||||||||||||
Arm description |
Left arm/ popliteal fossa: once daily application of TCS alone on the AD lesions Right arm/ popliteal fossa: twice daily application of the product RV4421A BS0042 in association with once daily application of TCS on the AD lesions (10 days) | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Topical corticosteroid
|
|||||||||||||||
Investigational medicinal product code |
Locapred 0.1%
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The TCS was applied once daily (evening only) on lesions of both study arms or popliteal fossa, before the test product if applicable. Two fingertip units of TCS were applied per study arm or popliteal fossa, at each application. If the patient presented other lesions on the study arm(s) or leg(s), he also applied
the associated product on these lesions. The first application of TCS was performed at the investigational centre.
|
|||||||||||||||
Investigational medicinal product name |
RV4421A-BS0042
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The test product had to be applied twice daily (morning and evening) on lesions of only one study arm or popliteal fossa according to randomization, after the associated product, if applicable. One fingertip unit of test product had to be applied on only one arm or popliteal fossa, at each application. If the patient presented other lesions on the same arm or the same leg, he would also apply the test product on these lesions. The first application of test product was performed at the investigational centre.
|
|||||||||||||||
|
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
Maintenance period
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
First Group | |||||||||||||||
Arm description |
Left arm: twice daily application of the product RV4421A BS0042 (2 weeks). Right arm: not any product application (2 weeks). | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
RV4421A-BS0042
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The test product had to be applied twice daily (morning and evening) on lesions of only one study arm or popliteal fossa according to randomization, after the associated product, if applicable. One fingertip unit of test product had to be applied on only one arm or popliteal fossa, at each application. If the patient presented other lesions on the same arm or the same leg, he would also apply the test product on these lesions. The first application of test product was performed at the investigational centre.
|
|||||||||||||||
Arm title
|
Second Group | |||||||||||||||
Arm description |
Left arm: no product was applied during the maintenance phase in this arm (2 weeks) Right arm: twice daily application of the product RV4421A BS0042 (2 weeks) | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
RV4421A-BS0042
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
The test product had to be applied twice daily (morning and evening) on lesions of only one study arm or popliteal fossa according to randomization, after the associated product, if applicable. One fingertip unit of test product had to be applied on only one arm or popliteal fossa, at each application. If the patient presented other lesions on the same arm or the same leg, he would also apply the test product on these lesions. The first application of test product was performed at the investigational centre.
|
|||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
First Period
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Fifty four patients with moderate to severe AD were included in the study. Fifty four patients were evaluated at D3 and D10, and 46 patients completed the study at D24. Eight patients discontinued during the study (before D24): 7 patients were not included in the 2nd period and 1 patient was withdrawn for a personal reason during the 2nd period. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
First Group
|
||
Reporting group description |
Left arm/popliteal fossa: twice daily application of the product RV4421A BS0042 in association with once daily application of TCS on the AD lesions (10 days) Right arm/ popliteal fossa: once daily application of TCS alone on the AD lesions | ||
Reporting group title |
Second Group
|
||
Reporting group description |
Left arm/ popliteal fossa: once daily application of TCS alone on the AD lesions Right arm/ popliteal fossa: twice daily application of the product RV4421A BS0042 in association with once daily application of TCS on the AD lesions (10 days) | ||
Reporting group title |
First Group
|
||
Reporting group description |
Left arm: twice daily application of the product RV4421A BS0042 (2 weeks). Right arm: not any product application (2 weeks). | ||
Reporting group title |
Second Group
|
||
Reporting group description |
Left arm: no product was applied during the maintenance phase in this arm (2 weeks) Right arm: twice daily application of the product RV4421A BS0042 (2 weeks) |
|
|||||||||||||
End point title |
L-SCORAD | ||||||||||||
End point description |
The LSCORAD is the sum of all SCORAD objective signs scores evaluated on a chosen target area.
The SCORAD objective signs were: erythema, oedema/papulation, oozing/crusts, excoriation, lichenification and xerosis.
For the primary efficacy criterion (L-SCORAD Index), if at least one evaluation was missing after the first evaluation of post product application, the LOCF method (Last Observation Carried Forward) was used to replace missing data.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
The primary criterion was the L-SCORAD index assessed independently on both elbow creases/study arms or popliteal fossa by the investigator on a scale ranged from 0 to 18, at Visit 2 (D3).
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
L-SCORAD | ||||||||||||
Comparison groups |
First Group v Second Group
|
||||||||||||
Number of subjects included in analysis |
54
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0005 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
F statistic | ||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
- | ||||||||||||
upper limit |
- |
|
|||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
At inclusion, any concomitant disease was reported. At each further visit, the occurrence of AE was determined by the patient’s spontaneous reporting, the investigator’s non-leading questioning and his/her clinical/dermatological evaluation.
|
||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The patient’s assessment had at least to take into account the following functional signs: burning sensation, warm sensation, itching/pruritus, tightness, stinging/prickling. The investigator and patient’s assessment had at least to take into account the following physical signs: redness/erythema swelling/oedema, desquamation, dryness, vesicles.
|
||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||
Dictionary name |
Not applicable | ||||||||||||||||||||||||||||||||||
Dictionary version |
NA
|
||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||
Reporting group title |
First + second Groups
|
||||||||||||||||||||||||||||||||||
Reporting group description |
Throughout the whole study, 16 patients out of 54 included patients (72%) experienced at least one adverse event suspected to be related to the test product and associated products and reported a total of 30 AEs. Serious adverse events (SAE) were not reported during this study. | ||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
06 Mar 2015 |
Modification of study areas:
Arms
In order to facilitate recruitment without changing the target population, it has been decided to extend the target areas from the elbow creases to the arms (including wrists). Indeed, in adults, atopic Dermatitis (AD) often appears in the elbow creases, but lesions affect also forearms and wrists.
Furthermore, in this study, each patient’s arm followed randomly a specific treatment regimen (either topical corticosteroids (TCS) alone, or association of TCS with RV4421A BS0042) and all scores (including primary criterion) were assessed independently on both sides. We considered that lesions on arms (including on wrists), similar in terms of extent and severity, didn't need to be symmetrical in terms of specific location on arms. For example, a patient could be included if he presented similar target lesions on the left wrist and the right elbow crease without impacting the study results. In order to have comparable data between all included patients, inclusion criteria related to disease severity were not modified.
Popliteal fossa
In order to make facilitate recruitment without changing the target population, it has been decided to extend the target areas not only on the arms, but also on the popliteal fossa. Popliteal fossa are areas commonly affected by inflammatory lesions in the adult population. Furthermore, AD often appears in these areas in a symmetrical distribution, perfectly adapted to an intra-individual study. According to several guidelines, moderately potent topical corticosteroids (TCS), like the one used in this study, are recommended for AD affecting the flexures. Both products are adapted to lesions affecting the popliteal fossa. We considered that a patient could be included if he presents similar lesions on the popliteal fossa without impacting the study results. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |